1. Home
  2. VEON vs CRSP Comparison

VEON vs CRSP Comparison

Compare VEON & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VEON
  • CRSP
  • Stock Information
  • Founded
  • VEON 1992
  • CRSP 2013
  • Country
  • VEON Netherlands
  • CRSP Switzerland
  • Employees
  • VEON N/A
  • CRSP N/A
  • Industry
  • VEON Telecommunications Equipment
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • VEON Telecommunications
  • CRSP Health Care
  • Exchange
  • VEON Nasdaq
  • CRSP Nasdaq
  • Market Cap
  • VEON 3.2B
  • CRSP 3.4B
  • IPO Year
  • VEON 1996
  • CRSP 2016
  • Fundamental
  • Price
  • VEON $38.00
  • CRSP $32.25
  • Analyst Decision
  • VEON Strong Buy
  • CRSP Buy
  • Analyst Count
  • VEON 1
  • CRSP 19
  • Target Price
  • VEON $60.00
  • CRSP $74.35
  • AVG Volume (30 Days)
  • VEON 120.8K
  • CRSP 1.8M
  • Earning Date
  • VEON 05-15-2025
  • CRSP 05-07-2025
  • Dividend Yield
  • VEON N/A
  • CRSP N/A
  • EPS Growth
  • VEON N/A
  • CRSP N/A
  • EPS
  • VEON 6.72
  • CRSP N/A
  • Revenue
  • VEON $4,004,000,000.00
  • CRSP $37,314,000.00
  • Revenue This Year
  • VEON $6.52
  • CRSP $49.76
  • Revenue Next Year
  • VEON $7.22
  • CRSP $275.55
  • P/E Ratio
  • VEON $6.55
  • CRSP N/A
  • Revenue Growth
  • VEON 8.39
  • CRSP N/A
  • 52 Week Low
  • VEON $22.35
  • CRSP $32.19
  • 52 Week High
  • VEON $48.39
  • CRSP $67.88
  • Technical
  • Relative Strength Index (RSI)
  • VEON 33.50
  • CRSP 28.44
  • Support Level
  • VEON $43.45
  • CRSP $32.96
  • Resistance Level
  • VEON $45.40
  • CRSP $42.72
  • Average True Range (ATR)
  • VEON 1.46
  • CRSP 1.67
  • MACD
  • VEON -0.45
  • CRSP -0.87
  • Stochastic Oscillator
  • VEON 5.60
  • CRSP 3.35

About VEON VEON Ltd. ADS

VEON Ltd is a provider of mobile and fixed-line connectivity as well as digital services. Currently, the company offers services to customers in the following countries: Pakistan, Ukraine, Kazakhstan, Bangladesh, Uzbekistan, and Kyrgyzstan. The reportable segments currently consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. The company provides services under the Beeline, Kyivstar, Banglalink and Jazz brands.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: